Table II.

Association of BRAF V600E/TERT promoter mutation status with clinicopathological characteristics in patients with papillary thyroid carcinoma.

					1 vs. 2		1 vs. 3		2 vs. 3
Clinicopathological features	BRAF −/TERT − (1) n=34	BRAF +/TERT − (2) n=163	BRAF +/−/TERT + (3) n=8	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value	OR (95% CI)	P-value
Sex
Female	26	130	5	0.484	0.825 (0.342-1.988)	0.668	1.950 (0.380-10.013)	0.412	2.364 (0.537-10.399)	0.367
Male	8	33	3
Age at diagnosis (years)
≤45	16	89	1	0.056	0.739 (0.352-1.550)	0.423	6.222 (0.689-56.203)	0.114	8.419 (1.013-69.989)	0.028a
>45	18	74	7
Tumor size (mm)
≤10	12	73	1	0.135	0.672 (0.312-1.450)	0.309	3.818 (0.419-34.812)	0.398	5.678 (0.683-47.204)	0.140
>10	22	90	7
Extrathyroidal invasion
No	24	86	1	0.009a	2.149 (0.966-4.779)	0.057	16.800 (1.822-154.894)	0.004a	7.818 (1.041-64.987)	0.032a
Yes	10	77	7
Multifocality
Single	24	84	1	0.008a	2.257 (1.015-5.019)	0.042a	16.800 (1.822-154.894)	0.004a	7.443 (0.895-61.866)	0.064
Multifocal	10	79	7
Lymph node metastasis
No	22	67	2	0.022a	2.627 (1.217-5.670)	0.012a	5.500 (1.021-31.589)	0.050	2.094 (0.410-10.691)	0.303
Yes	12	96	6
TNM stage
I–II	23	99	1	0.015a	1.352 (0.617-2.961)	0.450	14.636 (1.598-134.097)	0.013a	10.828 (1.301-90.097)	0.009a
III–IV	11	64	7

^aP<0.05. BRAF, B-Raf proto-oncogene; TERT, telomerase reverse transcriptase; OR, odds ratio; TNM, tumor/node/metastasis.